How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
64
RNA Quote, Financials, Valuation and Earnings
Last price:
$72.58
Seasonality move
:
9.46%
Day range:
$72.41 - $72.60
52-week range:
$21.51 - $72.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
456.65x
P/B ratio:
5.80x
Volume:
1M
Avg. volume:
1.8M
1-year change:
127.35%
Market cap:
$10.9B
Revenue:
$10.9M
EPS (TTM):
-$4.17
Analysts' Opinion
-
Consensus RatingAvidity Biosciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $74.64, Avidity Biosciences, Inc. has an estimated upside of 2.85% from its current price of $72.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $72.00 representing 100% downside risk from its current price of $72.57.
Fair Value
-
According to the consensus of 14 analysts, Avidity Biosciences, Inc. has 2.85% upside to fair value with a price target of $74.64 per share.
RNA vs. S&P 500
-
Over the past 5 trading days, Avidity Biosciences, Inc. has underperformed the S&P 500 by -1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avidity Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avidity Biosciences, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Avidity Biosciences, Inc. reported revenues of $12.5M.
Earnings Growth
-
Avidity Biosciences, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Avidity Biosciences, Inc. reported earnings per share of -$1.27.
Enterprise value:
9.1B
EV / Invested capital:
--
Price / LTM sales:
456.65x
EV / EBIT:
--
EV / Revenue:
436.49x
PEG ratio (5yr expected):
-0.40x
EV / Free cash flow:
-15.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$17.5M
Return On Assets:
-33.66%
Net Income Margin (TTM):
-2634.59%
Return On Equity:
-37.47%
Return On Invested Capital:
-37.09%
Operating Margin:
-1513.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.1M | $10.1M | $20.9M | $2.3M | $12.5M | |
| Gross Profit | $6.1M | $7.5M | $17.5M | $1.6M | $11.4M | |
| Operating Income | -$222.1M | -$324.7M | -$612.5M | -$98.1M | -$188.8M | |
| EBITDA | -$218.1M | -$322M | -$609.1M | -$97.4M | -$187.8M | |
| Diluted EPS | -$2.99 | -$2.90 | -$4.17 | -$0.65 | -$1.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $422M | $414.5M | $555.5M | $1.6B | $2B | |
| Total Assets | $425.9M | $430.5M | $573.2M | $1.6B | $2.1B | |
| Current Liabilities | $22.4M | $42.7M | $48.7M | $91.3M | $169.9M | |
| Total Liabilities | $31M | $53.6M | $55.7M | $137.4M | $247.9M | |
| Total Equity | $394.9M | $377M | $517.5M | $1.5B | $1.9B | |
| Total Debt | $877K | $8.2M | $7M | $3.8M | $46M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$174.8M | -$184.5M | -$580.5M | -$65.6M | -$156.2M | |
| Cash From Investing | -$188.9M | -$739M | -$309.4M | -$482.4M | -$587.9M | |
| Cash From Financing | $305.6M | $1.2B | $869.8M | $342.5M | $850.4M | |
| Free Cash Flow | -$179M | -$188.5M | -$592.3M | -$67.3M | -$156.9M | |
RNA
Sector
Market Cap
$10.9B
$24.3M
Price % of 52-Week High
99.77%
49.95%
Dividend Yield
0%
0%
Shareholder Yield
-13.73%
-1.67%
1-Year Price Total Return
127.35%
-21.37%
Beta (5-Year)
0.955
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.00
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$0.00
Relative Strength Index (RSI14)
Buy
Level
64.86
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-33.3333
50-day SMA
Buy
Level
$0.00
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.5726)
Buy
CA Score
(Annual)
Level (-0.2832)
Buy
Beneish M-Score
(Annual)
Level (-3.3486)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.413)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, RNA has received 2 Buy ratings 12 Hold ratings, and 0 Sell ratings. The RNA average analyst price target in the past 3 months is $74.64.
-
Where Will Avidity Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avidity Biosciences, Inc. share price will rise to $74.64 per share over the next 12 months.
-
What Do Analysts Say About Avidity Biosciences, Inc.?
Analysts are divided on their view about Avidity Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avidity Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $72.00.
-
What Is Avidity Biosciences, Inc.'s Price Target?
The price target for Avidity Biosciences, Inc. over the next 1-year time period is forecast to be $74.64 according to 14 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is RNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avidity Biosciences, Inc. is a Hold. 12 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RNA?
You can purchase shares of Avidity Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avidity Biosciences, Inc. shares.
-
What Is The Avidity Biosciences, Inc. Share Price Today?
Avidity Biosciences, Inc. was last trading at $72.58 per share. This represents the most recent stock quote for Avidity Biosciences, Inc.. Yesterday, Avidity Biosciences, Inc. closed at $72.57 per share.
-
How To Buy Avidity Biosciences, Inc. Stock Online?
In order to purchase Avidity Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RNA
Sector
P/E ratio
--
23.45x
PEG ratio
-0.40x
-0.01x
P/B ratio
5.80x
1.80x
Price / LTM sales
456.65x
1.53x
Growth Metrics
RNA
Sector
Revenue growth
434.03%
4.08%
Earnings growth
-94.11%
9.94%
Revenue (5-year growth)
36.27%
6.27%
Earnings forecast
-$1.25
-$0.19
Profitability
RNA
Sector
Profitability FY 2024
$8.1M
$3M
Return on invested capital
-37.09%
-33.25%
Return on assets
-33.66%
-29.67%
Return on equity
-37.47%
-38.71%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
9
Balance Sheet
RNA
Sector
Total cash
$1.9B
$25M
Short term investments
$1.3B
$25M
Total assets
$1.6B
$72.5M
Long term debt
$46M
$2.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
88
JNUG alert for Jan 30
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
